Therapeutic advances in small cell lung cancer

Bibliography

• PARKIN DM, PISANI P, FERLAY J: Global cancer statistics. Ca. Cancer J. Clin. (1999) 49:33–64.
   PubMed Web of Science ®Google Scholar
• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 1999. Ca. Cancel". Clin. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• LOWENBRAUN S, BARTOLUCCI A, SMALLEY RV, LYNN M, KRAUSS S, DURANT JR: The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer (1979) 44:406–413.
   PubMed Web of Science ®Google Scholar
• FUKUOKA M, FURUSE K, SAIJO N etal.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. (1991) 83:855–861.
   Google Scholar
• ROTH BJ, JOHNSON DH, EINHORN LH et al.: Randomized study of cyclophosphamide, doxorubicin and vincris-tine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Gun. Oncol. (1992) 10:282–291.
   Web of Science ®Google Scholar
• MCCRACKEN JD, JANAKI LM, CROWLEY JJ et al: Concur-rent chemotherapy /radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J. Clin. Oncol. (1990) 8:892–898.
   PubMed Web of Science ®Google Scholar
• KLASA RJ, MURRAY N, COLDMAN AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. (1991) 9:499–508.
   PubMed Web of Science ®Google Scholar
• IHDE DC: Chemotherapy of lung cancer. N Engl. J. Med. (1992) 327:1434–1441.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the concepts involved in thetreatment of patients with lung cancer.
   Google Scholar
• PIGNON JP, ARRIAGADA R, IHDE DC et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl. J. Med. (1992) 327:1618–1624.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis that offers insight into the degree of benefit required to alter standard therapy for SCLC.
   Google Scholar
• WARDE P, PAYNE D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J. UM. Oncol. (1992) 10:890–895.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis that offers insight into the degree of benefit required to alter standard therapy for SCLC.
   Google Scholar
• SANDLER AB: Current management of small cell lung cancer. Sem. Oncol. (1997) 24:463–476.
   PubMed Web of Science ®Google Scholar
• MURRAY N, COY P, PATER JL eta].: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1993) 11:336–344.
   Google Scholar
• TURRISI AT, KIM K, BLUM R et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. (1999) 340:265–271.
   PubMed Web of Science ®Google Scholar
• BUNN PA, CROWLEY J, HAZUKA M, TOLLEY R, LIVING-STON R: The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group. Proc. Am. Soc. Clin. Oncol. (1992) 11:292. Abstract 974.
   Google Scholar
• MOMIN F, KRAUT M, LATTIN P, VALDIVIESO M: Thrombocytopenia in patients receiving chemoradio-therapy and G-CSF for locally advanced nob-small cell lung cancer. Proc. Am. Soc. UM. Oncol (1992) 11:294. Abstract 983.
   Google Scholar
• AUPERIN A, ARRIAGADA R, PIGNON JP et al: Prophy-lactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl. J. Med. (1999) 341:476–484.
   PubMed Web of Science ®Google Scholar
• GREGOR A, CULL A, STEPHENS RJ et al.: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research and the European Organization for Research and Treatment of Cancer. Eur. J. Cancer (1997) 33:1752–1758.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA R, LE CHEVALIER T, BORIE F et al.: Prophy- lactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst. (1995) 87:183–190.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis that offers insight into the degree of benefit required to alter standard therapy for SCLC.
   Google Scholar
• SCHILLER JH, KIM K, HUTSON P et al.: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. (1996) 14:2345–2352.
   PubMed Web of Science ®Google Scholar
• ECKARDT J, PALMER MC, FANUCCHI M et al.: Oraltopotecan as single-agent first-line treatment for patients with extensive disease small cell lung cancer ineligible for standard IV therapy: a phase II study. Proc. Am. Soc. Clin. Oncol (1999) 18:501a. Abstract 1935.
   Google Scholar
• PEREZ-SOLER R, GLISSON BS, LEE JS et al.: Treatment ofpatients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. j Clin. Oncol (1996) 14:2785–2790.
   PubMed Web of Science ®Google Scholar
• ARDIZZONI A, HANSEN H, DOMBERNOWSKY P et al.:Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. (1997) 15:2090–2096.
   PubMed Web of Science ®Google Scholar
• VON POWELL J, GATZMEIER U, HARSTRICK A et al.: Amutlicentre randomised phase II study of oral topotecan versus IV topotecan for second line therapy in sensitive patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:471a. Abstract 1816.
   Google Scholar
• VON POWEL J, SCHILLER JH, SHEPHERD FA et al: Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. (1999) 17:658–667.
   PubMed Web of Science ®Google Scholar
• •This study emphasizes the importance of toxicity in the evaluation of new therapies for SCLC.
   Google Scholar
• TWEEDY CR, ANDREWS DF, BALL T: Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc. Am. Soc. Clin. Oncol. (1999) 18:525a. Abstract 2025.
   Google Scholar
• JACOBS S, JETT J, BELANI C et al.: Topotecan andpaclitaxel, an active couplet, in untreated extensive disease small cell lung cancer. Proc. Am. Soc. UM. Oncol. (1999) 18: 470a. Abstract 1814.
   Google Scholar
• ARDIZZONI A, MANEGOLD C, GAAFAR R et al.: Combina-tion chemotherapy with cisplatin and topotecan as second-line treatment of sensitive and refractory small cell lung cancer: an EORTC LCGG phase II study. Proc. Am. Soc. UM. Oncol. (1999) 18:471a. Abstract 1817.
   Google Scholar
• VAN ARK-OTTE J, KEDDE MA, VAN DER VIJGH WJ et al:Determinants of CPT-11 and SN-38 activities in human. Br. J. Cancer (1998) 77:2171–2176.
   PubMed Web of Science ®Google Scholar
• KUBOTA N, KANZAWA F, NISHIO K et al: Detection oftopoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. (1992) 188:571–577.
   PubMed Web of Science ®Google Scholar
• NEGORO S, FUKUOKA M, NIITANI H, TAGUCHI T: PhaseII study of CPT-11, a new camptothecin derivative, in small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1991) 10:241. Abstract 822.
   Google Scholar
• MASUDA N, FUKUOKA M, KUSUNOKI Y et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1992) 10:1225–1229.
   PubMed Web of Science ®Google Scholar
• FUKUDA M, NISHIO K, OGASAWARA H etal.: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small-cell lung cancer cells. Cancer Res. (1996) 56:789–793.
   Google Scholar
• PEI XH, NAKANISHI Y, TAKAYAMA K et al.: Effect of CPT-11 in combination with other anticancer agents. Anti-Cancer Drugs (1997) 8:231–237.
   PubMed Web of Science ®Google Scholar
• KUDOH S, FUJIWARA Y, TAKADA Y et al.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3) Japan Lung Cancer Group. J. Clin. Oncol (1998) 16:1068–1074.
   Google Scholar
• MASUDA N, MATSUI K, NEGORO S et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1998) 16:3329–3334.
   PubMed Web of Science ®Google Scholar
• TAMURA K, TAKADA M, KAWASE I et al: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jap. J. Cancer Res. (1997) 88:218–223.
   PubMedGoogle Scholar
• ETTINGER DS: Single-agent paclitaxel in the treatment of small cell lung cancer. Sem. Oncol. (1996) 23:16–17.
   PubMed Web of Science ®Google Scholar
• KIRSCHLING RJ, JUNG SH, JETT JR: A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. Proc. Am. Soc. Oncol. (1994) 18:326. Abstract 1076.
   Google Scholar
• SMIT EF, FOKKEMA E, BIESMA B, GROEN HJ, SNOEK W,POSTMUS PE: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br. J. Cancer (1998) 77:347–351.
   PubMed Web of Science ®Google Scholar
• LEVITAN N, DOWLATI A, CRAFFEY M et al.: A multi-institutional phase I/II trial of paclitaxel, cisplatin and etoposide with concurrent radiation and filgrastim support for limited-stage small cell lung carcinoma. Proc. Am. Soc. UM. Oncol (1999) 18:469a. Abstract 1809.
   Google Scholar
• GLISSON BS, KURIE JM, PEREZ-SOLER R et al.: Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J. Clin. Oncol. (1999) 17:2309–2315.
   PubMed Web of Science ®Google Scholar
• KELLY K, PAN Z, WOOD ME, MURPHY J, BUNN PA: Aphase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer. Clin. Cancer Res. (1999) 5:3419–3424.
   PubMed Web of Science ®Google Scholar
• BUNN PA, KELLY K, CROWLEY J, LIVINGSTON RB, GANDARA DR: Preliminary toxicity results from Southwest Oncology Group Trial 9705: a phase II trial of cisplatin, etoposide and paclitaxel with G-CSF in untreated patients with extensive small cell lung cancer. Proc. Am. Soc. UM. Oncol. (1999) 18:468a. Abstract 1807.
   Google Scholar
• HAINS WORTH JD, GRAY JR, STROUP SL et al.: Paclitaxel,carboplatin and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J. Clin. Oncol. (1997) 15:3464–3470.
   PubMed Web of Science ®Google Scholar
• DEPPERMANN KM, SERKE M, OEHM C et al.: Paclitaxel and carboplatin in advanced SCLC: a phase II study. Proc. Am. Soc. Clin. Oncol (1999) 18:482a. Abstract 1860.
   Google Scholar
• THOMAS P, LENA H, PAILLOTIN D A et al.: Preliminary report of paclitaxel/carboplatin phase II multicentric trial in patients with metastatic small cell lung cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:519a. Abstract 2000.
   Google Scholar
• GROEN HJM, FOKKEMA E, BIESMA B et al.: Paclitaxel andcarboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: a non-cross resistant schedule. J. Clin. Oncol. (1999) 17:927–932.
   PubMed Web of Science ®Google Scholar
• LAVELLE F, BISSERY MC, COMBEAU C, RIOU JF, VRIGNAUD P, ANDRE S: Preclinical evaluation of docetaxel (Taxotere). Sem. Oncol (1995) 22:3–16.
   Web of Science ®Google Scholar
• SMYTH JF, SMITH IE, SESSA C et al.: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur. J. Cancer (1994) 30A:1058–1060.
   Google Scholar
• LATREILLE J, CORMIER Y, MARTINS H, GOSS G, FISHER B,EISENHAUER E: Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small-cell lung cancer. Invest. New Drugs (1996) 13:343–345.
   PubMed Web of Science ®Google Scholar
• AOE K, KIURA K, UEOKA H et al: Effect of docetaxel withcisplatin or vinorelbine on lung cancer cell lines. AntiCancer Res. (1999) 19:291–299.
   PubMed Web of Science ®Google Scholar
• CORMIER Y, EISENHAUER E, MULDAL A et al.: Gemcita-bine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. (1994) 5:283–285.
   Google Scholar
• VAN DER LEE I, POSTMUS P, SMITE et al.: The activity of gemcitabine in patients with resistant small cell lung cancer: a phase II study. Proc. Am. Soc. Clin. Oncol (1999) 18:476a. Abstract 1835.
   Google Scholar
• RASSMANN J, THODTMANN R, DEPENBROCK H et al: Gemcitabine and etoposide in small-cell lung cancer: phase I and II trials. Sem. Oncol. (1997) 24:575–S78.
   Google Scholar
• EARLE CC, STEWART DJ, CORMIER Y et al.: A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer. Lung Cancer (1998) 22:235–241.
   PubMed Web of Science ®Google Scholar
• HIGANO CS, CROWLEY JJ, VEITH RV, LIVINGSTON RB: A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small-cell lung cancer, a Southwest Oncology Group study. Invest. New Drugs (1997) 15:153–156.
   PubMed Web of Science ®Google Scholar
• DEPIERRE A, LE CHAVLIER T, QUOIX E et al.: Phase II study of navelbine in small cell lung cancer. Proc. Am. Soc. Clin. Oncol (1995) 14:348. Abstract 1050.
   Google Scholar
• FURUSE K, KUBOTA K, KAWAHARA M et al.: Phase II study of vinorelbine in heavily previously treated small-cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology (1996) 53:169–172.
   Google Scholar
• JASSEM J, KARNICKA-MLODKOWSKA H, VAN POTTELS-BERGHE C et al.: Phase II study of vinorelbine (Navelbine) in previously treated small-cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur. J. Cancer (1993) 29A:1720–1722.
   Google Scholar
• GRIDELLI C, PERRONE F, IANNIELLO GP et al.:Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. J. UM. Oncol. (1998) 16:1414–1419.
   PubMed Web of Science ®Google Scholar
• KALEMKERIAN GP, MABRY M: Cellular and molecularbiology of small cell lung cancer. In: Lung Cancer. Roth JA, Cox JD, Hong WK (Eds.), Blackwell Scientific, Boston (1993):57–84. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• BEPLER G, ZEYMER U, MAHMOUD S et al.: Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides (1988) 9:1367–1372.
   PubMed Web of Science ®Google Scholar
• BUNN PA, CHAN D, STEWART J et al.: Effects of neuropeptide analogues on calcium flux and prolif-eration in lung cancer cell lines. Cancer Res. (1994) 54:3602–3610.
   PubMed Web of Science ®Google Scholar
• SECKL MJ, HIGGINS T, WIDMER F, ROZENGURT E: [D-Arg1,D-Trp5'7'9,Leu11] substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. (1997) 57:51–54.
   PubMed Web of Science ®Google Scholar
• LAYTON JE, SCANLON DB, SOVENY C, MORSTYN G: Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res. (1988) 48:4783–4789.
   PubMed Web of Science ®Google Scholar
• EVERARD MJ, MACAULAY VM, MILLER JL, SMITH IE: In vitro effects of substance P analogue [D-Argl, D-Phe5, D-Trp7'9, Leull] substance P on human tumour and normal cell growth. Br. J. Cancer (1992) 65:388–392.
   PubMed Web of Science ®Google Scholar
• LANGDON SP, SETHI T, RITCHIE A et al: Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. (1992) 52:4554–4557.
   PubMed Web of Science ®Google Scholar
• OROSZ A, SCHRETT J, NAGY J, BARTHA L, SCHON I, NYEKI 0: New short-chain analogs of a substance-P antagonist inhibit proliferation of human small-cell lung-cancer cells in vitro and in vivo. Int. J. Cancer (1995) 60:82–87.
   PubMed Web of Science ®Google Scholar
• SECKL MJ, ROZENGURT E: Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro. Eur. J. Cancer (1996) 32A:342–345.
   PubMed Web of Science ®Google Scholar
• ROSATI R, ADIL MR, ALI MA eta].: Induction of apoptosis by a short-chain neuropeptide analog in small cell lung cancer. Peptides (1998) 19:1519–1523.
   Google Scholar
• JONES DA, CUMMINGS J, LANGDON SP, SMYTH JF: Preclinical studies on the broad-spectrum neuropep-tide growth factor antagonist G. Gen. Pharmacol (1997) 28:183–189.
   PubMedGoogle Scholar
• ••A comprehensive review of the preclinical studies andrationale that support the clinical development of this neuropeptide antagonist.
   Google Scholar
• YANG HK, SCOTT FM, TREPEL JB, BATTEY JF, JOHNSON BE, KELLEY MJ: Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. Lung Cancer (1998) 21:165–175.
   PubMed Web of Science ®Google Scholar
• KELLEY MJ, LINNOILA RI, AVIS IL et al: Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small-cell lung cancer. Chest (1997) 112:256–261.
   PubMed Web of Science ®Google Scholar
• ••The first clinical trial of neuropeptide inhibition in SCLC.
   Google Scholar
• CHEN J, ZHOU JH, MOKOTOFF M, FANGER MW, BALLED: Lysis of small cell carcinoma of the lung cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide analog or a GRP antagonist. J. Hematotherapy (1995) 4:369–376.
   PubMedGoogle Scholar
• VANDERSPEK JC, SUTHERLAND JA, ZENG H, BATTEY JF, JENSEN RT, MURPHY JR: Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389GRP. Cancer Res. (1997) 57:290–294.
   PubMed Web of Science ®Google Scholar
• TRIFILIEFF A, LACH E, DUMONT P, GIES JP: Bradykinin binding sites in healthy and carcinomatous human lung. Br. J. Pharmacol. (1994) 111:1228–1232.
   PubMed Web of Science ®Google Scholar
• BUNN PA, CHAN D, JOHNSON G: Anti-growth factor therapy for lung cancer. Lung Cancer (1997) 18\(suppl 410–11.
   Google Scholar
• SETHI T, ROZENGURT E: Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res. (1991) 51:3621–3623.
   PubMed Web of Science ®Google Scholar
• STEWART JM, GERA L, CHAN DC, WHALLEY ET, HANSONWL, ZUZACK JS: Potent, long-acting, orally-active bradykinin antagonists for a wide range of applica-tions. Immunopharmacol. (1997) 36:167–172.
   PubMed Web of Science ®Google Scholar
• BUNN PA, CHAN D, JOHNSON G: Anti-growth factor therapy for lung cancer. Lung Cancer (1997) 18\(suppl 2):10–11.
   Google Scholar
• TALLETT A, CHILVERS ER, HANNAH S et al: Inhibition ofneuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Cancer Res. (1996) 56:4255–4263.
   PubMed Web of Science ®Google Scholar
• SEUFFERLEIN T, ROZENGURT E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell prolifera-tion and colony formation in small cell lung cancer cells. Cancer Res. (1996) 56:3895–3897.
   PubMed Web of Science ®Google Scholar
• COHEN AJ, BUNN PA, FRANKLIN W et al.: Neutralendopeptidase: variable expression in human lung, inactivation in lung cancer and modulation of peptide-induced calcium flux. Cancer Res. (1996) 56:831–839.
   PubMed Web of Science ®Google Scholar
• SHIPP MA, TARR GE, CHEN CY et al: CD10/neutralendopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA (1991) 88:10662–10666.
   Google Scholar
• BUNN PA, HELFRICH BA, BRENNER DG eta].: Effects ofrecombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin. Cancer Res. (1998) 4:2849–2858.
   Google Scholar
• RYGAARD K, NAKAMURA T, SPANG-THOMSEN M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer (1993) 67:37–46.
   PubMed Web of Science ®Google Scholar
• HIBI K, TAKAHASHI T, SEKIDO Y et al.: Coexpression ofthe stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene (1991) 6:2291-2296. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• KRYSTAL GW, HINES SJ, ORGAN CP: Autocrine growthof small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. (1996) 56:370–376.
   PubMed Web of Science ®Google Scholar
• YAMANISHI Y, MAEDA H, HIYAMA K, ISHIOKA S, YAMAKIDO M: Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts. Jap. J. Cancer Res. (1996) 87:534–542.
   PubMedGoogle Scholar
• KRYSTAL GW, CARLSON P, LITZ J: Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res. (1997) 57:2203–2208.
   PubMed Web of Science ®Google Scholar
• KRYSTAL GW, DEBERRY CS, LINNEKIN D, LITZ J: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PPL Cancer Res. (1998) 58:4660–4666.
   Google Scholar
• FISHER DE: Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 78:539–542.
   PubMed Web of Science ®Google Scholar
• •An excellent review of a new paradigm in cancer therapy.
   Google Scholar
• REED JC: Bc1-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am. (1995) 9:451–473.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the role of apoptotic pathways andmodulation in cancer therapy.
   Google Scholar
• IKEGAKI N, KATSUMATA M, MINNA J, TSUJIMOTO Y: Expression of bc1-2 in small cell lung carcinoma cells. Cancer Res. (1994) 54:6–8.
   PubMed Web of Science ®Google Scholar
• BEN-EZRA JM, KORNSTEIN MJ, GRIMES MM, KRYSTAL G: Small cell carcinomas of the lung express the Bc1-2 protein. Am. J. Pathol. (1994) 145:1036–1040.
   PubMed Web of Science ®Google Scholar
• OHMORI T, PODACK ER, NISHIO K et al.: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bc1-2. Biochem. Biophys. Res. Commun. (1993) 192:30–36.
   PubMed Web of Science ®Google Scholar
• ZIEGLER A, LUEDKE GH, FABBRO D et al.: Induction of apoptosis in small cell lung cancer by anti-sense oligonucleotide targeting the bc1-2 coding sequence. J. Natl Cancer Inst (1997) 89:1027–1036.
   PubMed Web of Science ®Google Scholar
• ••This paper presents proof-of-principle studies supportingthe modulation of apoptotic pathways as an anti-SCLC strategy.
   Google Scholar
• ZANGEMEISTER-WITTKE U, SCHENKER T, LUEDKE GH, STAHEL RA: Synergistic cytotoxicity of bc1-2 antisense oligonucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines. Br. J. Cancer (1998) 78:1035–1042.
   PubMed Web of Science ®Google Scholar
• •This study offers a biological rationale for combining molecularly targeted approaches with traditional cytotoxic therapy in developing novel treatments for SCLC.
   Google Scholar
• BLAGOSKLONNY MV, GIANNAKAKOU P, EL-DEIRY WS etRaf-1/bc1-2 phosphorylation: a step from microtu-bule damage to cell death. Cancer Res. (1997) 57:130–135.
   PubMed Web of Science ®Google Scholar
• PETTIT GR, KAMANO Y, HERALD CL et al.: The isolation and structure of a remarkable marine animal antineo-plastic constituent: dolastatin 10. J. Am. Chem. Soc. (1987) 109:6883–6885.
   Web of Science ®Google Scholar
• BAI R, FRIEDMAN SJ, PETTIT GR, HAMEL E: Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem. Pharmacol (1992) 43:2637–2645.
   PubMed Web of Science ®Google Scholar
• KALEMKERIAN GP, OU X, ADIL MR et al.: Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bc1-2 modifica-tion. Cancer Chemother. Pharmacol. (1999) 43:507–515.
   PubMed Web of Science ®Google Scholar
• ALI MA, ROSATI R, PETTIT GR, KALEMKERIAN GP: Dolastatin 15 induces apoptosis and BCL-2 phospho-rylation in small cell lung cancer cell lines. Anticancer Res. (1998) 18:1021–1026.
   PubMed Web of Science ®Google Scholar
• PITOT HC, MCELROY EAJ, REID JM et al.: Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. (1999) 5:525–531.
   PubMed Web of Science ®Google Scholar
• TRAN HT, NEWMAN RA, BECK DE, HUIE R, ABBRUZZESE JL, MADDEN T: A phase I pharmacokinetic/pharmaco-dynamic study of dolastatin-10 in adult patients with advanced solid tumors. Proc. Am. Assoc. Cancer Res. (1997) 38:307-308. Abstract 2056.
   Google Scholar
• SALVEN P, RUOTSALAINEN T, MATTSON K, JOENSUU H: High pre-treatment serum level of vascular endothe-lial growth factor is associated with poor outcome in small-cell lung cancer. Int. J. Cancer (1998) 79:144–146.
   PubMed Web of Science ®Google Scholar
• FUENTES R, ALLMAN R, MASON MD: Ganglioside expres-sion in lung cancer cell lines. Lung Cancer (1997) 18:21–33.
   PubMed Web of Science ®Google Scholar
• GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. (1999) 5:1319–1323.
   PubMed Web of Science ®Google Scholar
• •Promising, but very preliminary, data on the potential utility of a unique immunotherapy approach.
   Google Scholar